VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist
Title:
VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist
Author:
Torrente-Segarra, Vicenç Acosta Pereira, Asunción Morla, Rosa Ruiz, José Miguel Clavaguera, Teresa Figuls, Ramon Corominas, Hector Geli, Carme Roselló, Rosa de Agustín, Juan José Alegre, Cayetano Pérez, Carolina García, Angel Rodríguez de la Serna, Arturo
Appeared in:
Reumatologia clinica (English edition)
Paging:
Volume 12 (2016) nr. 6 pages 4 p.
Year:
2016
Contents:
Publisher:
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología